Extra-hepatic sources of FVIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of Hemophilia A mice

Disclosures: AF was supported by GGP09280 by Telethon Foundation Italy, and in part by ERC startup Grant n. 261178. SG was supported in part by NIH grants R01 DK 071111 and R01 DK 088561. AF and SG hold a patent: Application Number: US2011/000266, International Patent Application No. WO2011102890, Publication Date: August 25, 2011.

METHODS OF TREATMENT OF HEMOPHILIA no conflict of interest for the other authors

Contributions: DZ and SM designed and performed the experiments, analyzed data and wrote the paper. MF and MP developed the polyclonal anti-FVIII antibody and contributed to write the paper. GR and GV performed some experiments, analyzed data and contributed to write the paper. AA performed initial monocytes isolation and differentiation experiments. MZ, GG and AFerrero provided crucial human samples. SB provided assistance for the approval of ethical protocols for human samples. SG contributed to initial experimental design. SG, SB, MP and GG performed a critical revision of the manuscript. AF conceived the study, generated funding, designed the experiments, analyzed data and wrote the paper.